Ocular gene therapy via subretinal or intravitreal (IVT) injection offers a powerful means to treat devastating blinding diseases. However, natural AAV serotypes face critical delivery bottlenecks within the dense structural matrices of the eye (such as the Internal Limiting Membrane, ILM, and Interphotoreceptor Matrix). Conventional vectors often show limited penetration, non-specific tropism, and require high viral loads—which frequently trigger intraocular inflammation, uveitis, and off-target toxicities.
To overcome these obstacles, Protheragen presents the ophthalmic targeted vector delivery technology platform. By integrating next-generation engineered synthetic AAV capsids with retina-restricted gene expression cassettes, our platform ensures deep retinal tissue penetration, cellular specificity (such as RPE, photoreceptors, and retinal ganglion cells), and robust transgene expression at reduced therapeutic doses.
Fig.1 AAV vector structures and ocular delivery routes. (Kim, T.H., et al., 2026)
Engineered Ocular Capsid Variants (Next-Gen Tropism)
Utilizes directed evolution and rational capsid surface engineering (peptide insertions, tyrosine/threonine mutation) to select AAV capsids capable of bypassing dense ocular physical barriers and achieving enhanced tropism for target cell populations.
Cell-Type Specific Expression Cascades
Pairs engineered capsids with ultra-compact, cell-restricted promoters (e.g., VMD2/BEST1 for RPE, hRK/GRK1 for photoreceptors) to ensure zero transgene expression leakage into non-target ocular tissues.
Optimized Dose-Efficiency & Immunogenicity Reduction
Achieves higher viral infectivity and functional gene expression at significantly lower vector genome (VG) doses per eye, effectively preserving ocular immune privilege and preventing treatment-emergent intraocular inflammation.
Protheragen offers tailored CRO/CDMO solutions to optimize ocular target delivery for your gene therapy candidates:
High-throughput screening of synthetic AAV capsid libraries for specific target cell tropism (RPE, Photoreceptors, Glial cells, RGCs).
Engineering retina-specific promoter and regulatory element constructs to restrict transgene expression strictly to target ocular cell types.
High-purity packaging with ultra-low empty capsid ratios (<10%) and strict endotoxin control optimized for intraocular injection.
dPCR, RT-qPCR, and spatial fluorescence/immunohistochemistry profiling across dissected ocular layers (cornea, iris, vitreous, retina, RPE-choroid).
Our Ophthalmic Targeted Vector Delivery Platform is tailored for precision delivery across major inherited and acquired blinding conditions (including but not limited to):
Retinal Pigment Epithelium (RPE) & Photoreceptor Diseases
Ocular Vascular & Macular Disorders
Optic Nerve & Ganglion Cell Disorders
Protheragen provides an integrated, end-to-end platform for ophthalmic gene therapy development. By uniting advanced AAV capsid evolution, retina-specific expression cassette design, and specialized intraocular delivery validation, we help you bypass the traditional hurdles of ocular vector development. Partner with Protheragen to build safer, highly targeted AAV candidates that maximize therapeutic efficacy while safeguarding ocular immune privilege.
Talk to our ophthalmic vector experts today to discuss your target cell profile, select engineered capsids, or request a customized proposal.
Reference
Our AAVLinkTM platform is at the forefront of adeno-associated viral (AAV) vector development, leveraging our extensive expertise and state-of-the-art technologies to drive innovation in gene therapy.
